Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance.

Sale MJ, Balmanno K, Saxena J, Ozono E, Wojdyla K, McIntyre RE, Gilley R, Woroniuk A, Howarth KD, Hughes G, Dry JR, Arends MJ, Caro P, Oxley D, Ashton S, Adams DJ, Saez-Rodriguez J, Smith PD, Cook SJ.

Nat Commun. 2019 May 2;10(1):2030. doi: 10.1038/s41467-019-09438-w.

2.

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.

Floc'h N, Ashton S, Ferguson D, Taylor P, Carnevalli LS, Hughes AM, Harris E, Hattersley M, Wen S, Curtis NJ, Pilling JE, Young LA, Maratea K, Pease EJ, Barry ST.

Mol Cancer Ther. 2019 May;18(5):909-919. doi: 10.1158/1535-7163.MCT-18-0577. Epub 2019 Mar 14.

PMID:
30872381
3.

Microglial Phagocytosis of Newborn Cells Is Induced by Endocannabinoids and Sculpts Sex Differences in Juvenile Rat Social Play.

VanRyzin JW, Marquardt AE, Argue KJ, Vecchiarelli HA, Ashton SE, Arambula SE, Hill MN, McCarthy MM.

Neuron. 2019 Apr 17;102(2):435-449.e6. doi: 10.1016/j.neuron.2019.02.006. Epub 2019 Feb 28.

PMID:
30827729
4.

Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival.

Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, Flaifel A, Novak JS, Gulati A, Buss E, Younger ST, McBrayer SK, Cowley GS, Bonal DM, Nguyen QD, Brulle-Soumare L, Taylor P, Cairo S, Ryan CJ, Pease EJ, Maratea K, Travers J, Root DE, Signoretti S, Pellman D, Ashton S, Lord CJ, Barry ST, Kaelin WG Jr.

Cancer Discov. 2019 Feb;9(2):230-247. doi: 10.1158/2159-8290.CD-18-0389. Epub 2018 Oct 29.

5.

First trimester placental endothelial cells from pregnancies with abnormal uterine artery Doppler are more sensitive to apoptotic stimuli.

Charolidi N, Host AJ, Ashton S, Tryfonos Z, Leslie K, Thilaganathan B, Cartwright JE, Whitley GS.

Lab Invest. 2019 Mar;99(3):411-420. doi: 10.1038/s41374-018-0139-z. Epub 2018 Oct 5.

6.

Visible Light-Activated CO Release and 1O2 Photosensitizer Formation with Ru(II),Mn(I) Complexes.

Pickens RN, Neyhouse BJ, Reed DT, Ashton ST, White JK.

Inorg Chem. 2018 Sep 17;57(18):11616-11625. doi: 10.1021/acs.inorgchem.8b01759. Epub 2018 Aug 30.

PMID:
30160480
7.

Zika prevention: lessons from the Australian front line.

Mudd J, Hollins A, Ashton S, Gair R, Donohue S.

Aust N Z J Public Health. 2018 Dec;42(6):510-512. doi: 10.1111/1753-6405.12814. Epub 2018 Aug 8. No abstract available.

PMID:
30088678
8.

Sex and seasonal differences in mRNA expression of estrogen receptor α (ESR1) in red-sided garter snakes (Thamnophis sirtalis parietalis).

Ashton SE, Vernasco BJ, Moore IT, Parker MR.

Gen Comp Endocrinol. 2018 Oct 1;267:59-65. doi: 10.1016/j.ygcen.2018.05.026. Epub 2018 May 25.

PMID:
29807033
9.

Women's Experiences of Pornography: A Systematic Review of Research Using Qualitative Methods.

Ashton S, McDonald K, Kirkman M.

J Sex Res. 2018 Mar-Apr;55(3):334-347. doi: 10.1080/00224499.2017.1364337. Epub 2017 Sep 21.

PMID:
28933950
10.

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.

Floc'h N, Ashton S, Taylor P, Trueman D, Harris E, Odedra R, Maratea K, Derbyshire N, Caddy J, Jacobs VN, Hattersley M, Wen S, Curtis NJ, Pilling JE, Pease EJ, Barry ST.

Mol Cancer Ther. 2017 Jun;16(6):1031-1040. doi: 10.1158/1535-7163.MCT-16-0580. Epub 2017 Mar 14.

11.

Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma.

Martin MJ, Eberlein C, Taylor M, Ashton S, Robinson D, Cross D.

Oncotarget. 2016 Dec 27;7(52):86313-86325. doi: 10.18632/oncotarget.13388.

12.

Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104.

Yates JW, Ashton S, Cross D, Mellor MJ, Powell SJ, Ballard P.

Mol Cancer Ther. 2016 Oct;15(10):2378-2387. Epub 2016 Jul 20.

13.

Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.

Hennessy EJ, Chuaqui C, Ashton S, Colclough N, Cross DA, Debreczeni JÉ, Eberlein C, Gingipalli L, Klinowska TC, Orme JP, Sha L, Wu X.

ACS Med Chem Lett. 2016 Mar 21;7(5):514-9. doi: 10.1021/acsmedchemlett.6b00058. eCollection 2016 May 12.

14.

A novel in situ hydrophobic ion paring (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system.

Song YH, Shin E, Wang H, Nolan J, Low S, Parsons D, Zale S, Ashton S, Ashford M, Ali M, Thrasher D, Boylan N, Troiano G.

J Control Release. 2016 May 10;229:106-119. doi: 10.1016/j.jconrel.2016.03.026. Epub 2016 Mar 18.

PMID:
27001894
15.

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.

Ashton S, Song YH, Nolan J, Cadogan E, Murray J, Odedra R, Foster J, Hall PA, Low S, Taylor P, Ellston R, Polanska UM, Wilson J, Howes C, Smith A, Goodwin RJ, Swales JG, Strittmatter N, Takáts Z, Nilsson A, Andren P, Trueman D, Walker M, Reimer CL, Troiano G, Parsons D, De Witt D, Ashford M, Hrkach J, Zale S, Jewsbury PJ, Barry ST.

Sci Transl Med. 2016 Feb 10;8(325):325ra17. doi: 10.1126/scitranslmed.aad2355.

16.

PDGFR Inhibition Results in Pericyte Depletion and Hemorrhage into the Corpus Luteum of the Rat Ovary.

Hall AP, Ashton S, Horner J, Wilson Z, Reens J, Richmond GH, Barry ST, Wedge SR.

Toxicol Pathol. 2016 Jan;44(1):98-111. doi: 10.1177/0192623315613452. Epub 2015 Nov 3.

PMID:
26534939
17.

Increased apoptosis, altered oxygen signaling, and antioxidant defenses in first-trimester pregnancies with high-resistance uterine artery blood flow.

Leslie K, Whitley GS, Herse F, Dechend R, Ashton SV, Laing K, Thilaganathan B, Cartwright JE.

Am J Pathol. 2015 Oct;185(10):2731-41. doi: 10.1016/j.ajpath.2015.06.020. Epub 2015 Sep 8.

PMID:
26362067
18.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL.

J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1.

PMID:
25271963
19.

Researcher or nurse? Difficulties of undertaking semi-structured interviews on sensitive topics.

Ashton S.

Nurse Res. 2014 Sep;22(1):27-31. doi: 10.7748/nr.22.1.27.e1255.

PMID:
25251817
20.

End of life care: The experiences of advance care planning amongst family caregivers of people with advanced dementia - A qualitative study.

Ashton SE, Roe B, Jack B, McClelland B.

Dementia (London). 2016 Sep;15(5):958-75. doi: 10.1177/1471301214548521. Epub 2014 Sep 3.

PMID:
25187482
21.

Leadership walkrounds in mental health care.

Ashton S.

Nurs Times. 2014 Jun 4-10;110(23):21-3.

PMID:
25016736
22.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W.

Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.

23.

End of life discussion in an academic family health team in kingston, ontario, Canada.

French R, Zhang W, Parks K, Ashton S, Dumas M, Haider A, Leung L.

J Family Med Prim Care. 2013 Jul;2(3):263-5. doi: 10.4103/2249-4863.120749.

24.

Endogenous and xenobiotic metabolite profiling of liver extracts from SCID and chimeric humanized mice following repeated oral administration of troglitazone.

Barnes AJ, Baker DR, Hobby K, Ashton S, Michopoulos F, Spagou K, Loftus NJ, Wilson ID.

Xenobiotica. 2014 Jan;44(2):174-85. doi: 10.3109/00498254.2013.867463. Epub 2013 Dec 18.

PMID:
24350779
25.

Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).

Ward RA, Anderton MJ, Ashton S, Bethel PA, Box M, Butterworth S, Colclough N, Chorley CG, Chuaqui C, Cross DA, Dakin LA, Debreczeni JÉ, Eberlein C, Finlay MR, Hill GB, Grist M, Klinowska TC, Lane C, Martin S, Orme JP, Smith P, Wang F, Waring MJ.

J Med Chem. 2013 Sep 12;56(17):7025-48. doi: 10.1021/jm400822z. Epub 2013 Aug 30.

PMID:
23930994
27.

The effect of particle proximity on the oxygen reduction rate of size-selected platinum clusters.

Nesselberger M, Roefzaad M, Hamou RF, Biedermann PU, Schweinberger FF, Kunz S, Schloegl K, Wiberg GK, Ashton S, Heiz U, Mayrhofer KJ, Arenz M.

Nat Mater. 2013 Oct;12(10):919-24. doi: 10.1038/nmat3712. Epub 2013 Jul 21.

PMID:
23872730
28.

Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies.

Farren M, Weston S, Brown H, Broadbent N, Powell S, Shaw R, Smith NR, Inglis R, Graham A, Ashton S, Wedge SR, Barry ST.

Angiogenesis. 2012 Dec;15(4):555-68. doi: 10.1007/s10456-012-9280-2. Epub 2012 May 27.

PMID:
22644562
29.

Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.

Plé PA, Jung F, Ashton S, Hennequin L, Laine R, Lambert-van der Brempt C, Morgentin R, Pasquet G, Taylor S.

Bioorg Med Chem Lett. 2012 May 1;22(9):3050-5. doi: 10.1016/j.bmcl.2012.03.074. Epub 2012 Mar 28.

PMID:
22497760
30.

Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases.

Plé PA, Jung F, Ashton S, Hennequin L, Laine R, Morgentin R, Pasquet G, Taylor S.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):262-6. doi: 10.1016/j.bmcl.2011.11.019. Epub 2011 Nov 12.

PMID:
22153662
31.

A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis.

Elewski B, Pollak R, Ashton S, Rich P, Schlessinger J, Tavakkol A.

Br J Dermatol. 2012 Feb;166(2):389-98. doi: 10.1111/j.1365-2133.2011.10660.x. Epub 2011 Dec 6.

PMID:
21967490
32.

The particle size effect on the oxygen reduction reaction activity of Pt catalysts: influence of electrolyte and relation to single crystal models.

Nesselberger M, Ashton S, Meier JC, Katsounaros I, Mayrhofer KJ, Arenz M.

J Am Chem Soc. 2011 Nov 2;133(43):17428-33. doi: 10.1021/ja207016u. Epub 2011 Oct 11.

PMID:
21950956
33.

Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.

Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST.

Mol Cancer Ther. 2011 May;10(5):861-73. doi: 10.1158/1535-7163.MCT-10-0976. Epub 2011 Mar 25.

34.

Using compliments to measure quality.

Ashton S.

Nurs Times. 2011 Feb 22-28;107(7):14-5.

PMID:
21409996
35.

Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.

Tazzyman S, Barry ST, Ashton S, Wood P, Blakey D, Lewis CE, Murdoch C.

Int J Cancer. 2011 Aug 15;129(4):847-58. doi: 10.1002/ijc.25987. Epub 2011 Apr 13.

36.

Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation.

Fan H, Wong D, Ashton SH, Borg KT, Halushka PV, Cook JA.

Inflammation. 2012 Feb;35(1):130-7. doi: 10.1007/s10753-011-9297-5.

37.

Metabonomic investigation of liver profiles of nonpolar metabolites obtained from alcohol-dosed rats and mice using high mass accuracy MSn analysis.

Loftus N, Barnes A, Ashton S, Michopoulos F, Theodoridis G, Wilson I, Ji C, Kaplowitz N.

J Proteome Res. 2011 Feb 4;10(2):705-13. doi: 10.1021/pr100885w. Epub 2010 Dec 9.

38.

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, Jürgensmeier JM, Womack C.

Clin Cancer Res. 2010 Jul 15;16(14):3548-61. doi: 10.1158/1078-0432.CCR-09-2797. Epub 2010 Jul 6.

39.

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.

Fens MH, Hill KJ, Issa J, Ashton SE, Westwood FR, Blakey DC, Storm G, Ryan AJ, Schiffelers RM.

Br J Cancer. 2008 Oct 21;99(8):1256-64. doi: 10.1038/sj.bjc.6604675. Epub 2008 Sep 16.

40.

Peroxisome proliferator activated receptor gamma is not necessary for the development of LPS-induced tolerance in macrophages.

Zingarelli B, Fan H, Ashton S, Piraino G, Mangeshkar P, Cook JA.

Immunology. 2008 May;124(1):51-7. Epub 2007 Nov 17.

41.

Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats.

Gould S, Westwood FR, Curwen JO, Ashton SE, Roberts DW, Lovick SC, Ryan AJ.

J Natl Cancer Inst. 2007 Nov 21;99(22):1724-8. Epub 2007 Nov 13.

PMID:
18000220
42.

Haemolytic uraemic syndrome associated with a family cluster of enterohaemorrhagic Escherichia coli.

Hanna JN, Humphreys JL, Ashton SE, Murphy DM.

Commun Dis Intell Q Rep. 2007 Sep;31(3):300-3. No abstract available.

43.

Distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative (14C-ZD6126) to tumour-bearing mice.

D'Souza RA, Partridge EA, Roberts DW, Ashton S, Ryan A, Patterson AB, Wilson Z, Thurrell CC.

Xenobiotica. 2007 Mar;37(3):328-40.

PMID:
17624029
44.

Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats.

Bradley DP, Tessier JJ, Ashton SE, Waterton JC, Wilson Z, Worthington PL, Ryan AJ.

Neoplasia. 2007 May;9(5):382-91.

45.

Understanding behavior change for women experiencing intimate partner violence: mapping the ups and downs using the stages of change.

Chang JC, Dado D, Ashton S, Hawker L, Cluss PA, Buranosky R, Scholle SH.

Patient Educ Couns. 2006 Sep;62(3):330-9. Epub 2006 Jul 24.

PMID:
16860522
46.

Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126.

Cullis ER, Kalber TL, Ashton SE, Cartwright JE, Griffiths JR, Ryan AJ, Robinson SP.

Microvasc Res. 2006 Mar;71(2):76-84. Epub 2006 Mar 10.

PMID:
16530791
47.

Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs.

Reigan P, Edwards PN, Gbaj A, Cole C, Barry ST, Page KM, Ashton SE, Luke RW, Douglas KT, Stratford IJ, Jaffar M, Bryce RA, Freeman S.

J Med Chem. 2005 Jan 27;48(2):392-402.

PMID:
15658853
48.

Uterine spiral artery remodeling involves endothelial apoptosis induced by extravillous trophoblasts through Fas/FasL interactions.

Ashton SV, Whitley GS, Dash PR, Wareing M, Crocker IP, Baker PN, Cartwright JE.

Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):102-8. Epub 2004 Oct 21.

49.

Cognitive processing in monozygotic twins discordant for chronic fatigue syndrome.

Mahurin RK, Claypoole KH, Goldberg JH, Arguelles L, Ashton S, Buchwald D.

Neuropsychology. 2004 Apr;18(2):232-9.

PMID:
15099145
50.

Barriers to evidence based practice in primary care: a review of the literature.

McKenna H, Ashton S, Keeney S.

Int J Nurs Stud. 2004 May;41(4):369-78. Review.

PMID:
15050848

Supplemental Content

Loading ...
Support Center